vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $123.8M, roughly 1.5× NATURES SUNSHINE PRODUCTS INC). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 3.3%, a 44.6% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -21.9%). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -15.4%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
NATR vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $188.3M |
| Net Profit | $4.1M | $90.3M |
| Gross Margin | 72.5% | 79.5% |
| Operating Margin | 4.3% | 32.3% |
| Net Margin | 3.3% | 47.9% |
| Revenue YoY | 4.7% | -21.9% |
| Net Profit YoY | 1379.4% | 1710.8% |
| EPS (diluted) | $0.23 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $188.3M | ||
| Q3 25 | $128.3M | $215.3M | ||
| Q2 25 | $114.8M | $188.2M | ||
| Q1 25 | $113.2M | $197.2M | ||
| Q4 24 | $118.2M | $241.0M | ||
| Q3 24 | $114.6M | $225.5M | ||
| Q2 24 | $110.6M | $256.0M | ||
| Q1 24 | $111.0M | $263.4M |
| Q4 25 | $4.1M | $90.3M | ||
| Q3 25 | $5.3M | $91.1M | ||
| Q2 25 | $5.3M | $139.5M | ||
| Q1 25 | $4.7M | $-10.0M | ||
| Q4 24 | $-321.0K | $-5.6M | ||
| Q3 24 | $4.3M | $-284.4M | ||
| Q2 24 | $1.3M | $-433.6M | ||
| Q1 24 | $2.3M | $-49.2M |
| Q4 25 | 72.5% | 79.5% | ||
| Q3 25 | 73.3% | 83.7% | ||
| Q2 25 | 71.7% | 81.3% | ||
| Q1 25 | 72.1% | 81.4% | ||
| Q4 24 | 72.0% | 79.8% | ||
| Q3 24 | 71.3% | 82.1% | ||
| Q2 24 | 71.4% | 84.5% | ||
| Q1 24 | 71.2% | 85.3% |
| Q4 25 | 4.3% | 32.3% | ||
| Q3 25 | 7.0% | 30.4% | ||
| Q2 25 | 3.7% | 5.7% | ||
| Q1 25 | 5.4% | -31.2% | ||
| Q4 24 | 3.8% | -69.2% | ||
| Q3 24 | 4.6% | -36.4% | ||
| Q2 24 | 5.1% | -90.8% | ||
| Q1 24 | 4.2% | -6.1% |
| Q4 25 | 3.3% | 47.9% | ||
| Q3 25 | 4.2% | 42.3% | ||
| Q2 25 | 4.6% | 74.1% | ||
| Q1 25 | 4.2% | -5.1% | ||
| Q4 24 | -0.3% | -2.3% | ||
| Q3 24 | 3.8% | -126.1% | ||
| Q2 24 | 1.2% | -169.4% | ||
| Q1 24 | 2.1% | -18.7% |
| Q4 25 | $0.23 | $2.78 | ||
| Q3 25 | $0.30 | $2.91 | ||
| Q2 25 | $0.28 | $4.50 | ||
| Q1 25 | $0.25 | $-0.39 | ||
| Q4 24 | $-0.02 | $-0.01 | ||
| Q3 24 | $0.23 | $-9.39 | ||
| Q2 24 | $0.07 | $-14.35 | ||
| Q1 24 | $0.12 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $161.6M | $-171.5M |
| Total Assets | $261.1M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $226.6M | ||
| Q3 25 | $95.6M | $184.2M | ||
| Q2 25 | $81.3M | $267.4M | ||
| Q1 25 | $86.5M | $138.3M | ||
| Q4 24 | $84.7M | $146.9M | ||
| Q3 24 | $78.7M | $159.2M | ||
| Q2 24 | $68.7M | $236.9M | ||
| Q1 24 | $77.8M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | $-171.5M | ||
| Q3 25 | $166.7M | $-260.5M | ||
| Q2 25 | $163.7M | $-351.7M | ||
| Q1 25 | $167.1M | $-496.8M | ||
| Q4 24 | $161.0M | $-488.2M | ||
| Q3 24 | $162.6M | $-497.6M | ||
| Q2 24 | $156.4M | $-218.3M | ||
| Q1 24 | $159.7M | $228.4M |
| Q4 25 | $261.1M | $1.7B | ||
| Q3 25 | $264.8M | $1.7B | ||
| Q2 25 | $254.9M | $1.5B | ||
| Q1 25 | $252.7M | $1.5B | ||
| Q4 24 | $240.9M | $1.8B | ||
| Q3 24 | $245.3M | $2.2B | ||
| Q2 24 | $235.8M | $3.2B | ||
| Q1 24 | $247.3M | $5.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $26.2M |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $26.2M | ||
| Q3 25 | $18.5M | $-60.6M | ||
| Q2 25 | $4.3M | $-25.6M | ||
| Q1 25 | $2.6M | $184.0K | ||
| Q4 24 | $12.2M | $-2.7M | ||
| Q3 24 | $9.6M | $19.5M | ||
| Q2 24 | $1.3M | $111.5M | ||
| Q1 24 | $2.2M | $135.4M |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 2.41× | 0.29× | ||
| Q3 25 | 3.46× | -0.66× | ||
| Q2 25 | 0.81× | -0.18× | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
